Rac1 repression reverses chemoresistance by targeting tumor metabolism
Shanmugasundaram Ganapathy-Kanniappan1
1Russell H. Morgan Department of Radiology and Radiological Science, Division of Interventional Radiology, The Johns Hopkins University School of Medicine , Baltimore, MD, USA.
Cancer Biology & Therapy
|September 1, 2020
Summary
Researchers found that targeting Rac1 (GTP binding protein) in breast cancer can overcome chemoresistance. Disrupting Rac1 activity sensitizes cancer cells to DNA-damaging drugs by regulating the pentose phosphate pathway (PPP).
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Tumor metabolism is characterized by increased glucose utilization, fueling cancer cell growth and survival.
- The glycolytic flux and pentose phosphate pathway (PPP) are crucial for neoplastic cell proliferation.
- Rac1 (GTP binding protein) has been identified as a factor in human breast cancer therapy resistance.
Purpose of the Study:
- To investigate the role of Rac1 in chemoresistance in human breast cancer.
- To explore the regulatory mechanisms of Rac1 in the pentose phosphate pathway (PPP).
- To assess the potential of targeting Rac1 to enhance chemosensitivity.
Main Methods:
- Utilized multiple experimental approaches to study Rac1 activity in breast cancer cells.
- Investigated the impact of Rac1 disruption on cellular response to DNA-damaging agents.
- Assessed the in vivo efficacy of targeting Rac1.
Main Results:
- Rac1 promotes chemoresistance in breast cancer by upregulating glycolytic flux and PPP.
- Disruption of Rac1 activity sensitizes cancer cells to DNA-damaging therapeutics.
- Rac1 plays a previously unrecognized role in regulating the PPP in breast cancer.
Conclusions:
- Rac1 is a key regulator of metabolic pathways contributing to breast cancer chemoresistance.
- Targeting Rac1 activity can enhance the effectiveness of DNA-damaging chemotherapy.
- In vivo targeting of Rac1 is a feasible strategy to improve breast cancer treatment outcomes.
Related Concept Videos
02:56Treatment Resistant Cancers
3.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
01:20The Retinoblastoma Gene
4.5K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.5K
02:57Targeted Cancer Therapies
8.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.5K
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
419
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
419
02:53Adaptive Mechanisms in Cancer Cells
6.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.7K
03:03mTOR Signaling and Cancer Progression
4.5K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.5K